RVNC—ASPEN-OLS open-label safety study in CD is fully enrolled with 354 patients (reduced from original goal due to COVID). Data from ASPEN-OLS will be reported in 2021. Source: Today’s CC.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”